Boldly transforming the lives of individuals with rare neurological diseases
boldvision
Science-driven and patient-focused, our mission is to bring treatments to individuals with rare diseases who have little or no treatment options.
boldscience
Our deep understanding of human genetics and cellular function enables us to translate discoveries into meaningful therapies for rare neurological diseases.
boldcommitment
At Ovid, we seek to understand what matters most to individuals with rare diseases and their families. We are committed to address the challenges they face every day.
investor info
Stock quote
NASDAQ: OVID
$3.55
-1.93
20.02.20 | 11:18 AM EST
Copyright West LLC. Minimum 15 minutes delayed.
recent insights
- Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
- Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020
- Ovid Therapeutics to Participate at the 31st Annual Piper Jaffray Healthcare Conference
- Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer
boldpeople
Each team member understands the difference between a drug and a medicine—one is a product, the other changes lives—and that's what brings us together as Ovidians.